WHC est encore en dévelopement. Lisez ceci pour comprendre notre approche.
depiction of UQCNKQCJZOAFTQ-UHFFFAOYSA-N.svg
tripsit

oxymorphone

Vérifier sur tripsit

psychonaut

Oxymorphone

Vérifier sur psychonaut

isomerdesign

Oxymorphone

Vérifier sur isomerdesign

pubchem

Oxymorphone

Vérifier sur pubchem

druglab

Oxymorphone

Vérifier sur druglab

drugmap

Oxymorphone

Vérifier sur drugmap

wiki

Oxymorphone

Vérifier sur wiki

Data

InChI: InChI=1S/C17H19NO4/c1-18-7-6-16-13-9-2-3-10(19)14(13)22-15(16)11(20)4-5-17(16,21)12(18)8-9/h2-3,12,15,19,21H,4-8H2,1H3

Synonymes: Oxymorphone (abuse-resistant, pain), Pain Therapeutics/ King Pharmaceuticals,76-41-5,UNII-9VXA968E0C,BDBM50001707,10,17-dihydroxy-4-methyl-(13R,17S)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10-trien-14-one(oxymorphone),EN3202,10,17-dihydroxy-4-methyl-(13R,17S)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10-trien-14-one,EINECS 200-959-7,CHEBI:7865,Numorphan,Morphinan-6-one,5-epoxy-3,14-dihydroxy-17-methyl-, (5.alpha.)-,Dihydro-14-hydroxymorphinone,Q423380,Oxymorphone 1.0 mg/ml in Methanol,(5alpha)-3,14-dihydroxy-17-methyl-4,5-epoxymorphinan-6-one,14-Hydroxydihydromophone,Morphinan-6-one, 3,14-dihydroxy-4,5-alpha-epoxy-17-methyl-,NIH10323,C08019,Morphinan-6-one, 4,5-epoxy-3,14-dihydroxy-17-methyl-, (5-alpha)-,4,5alpha-Epoxy-3,14-dihydroxy-17-methyl morphinan-6-one,DB01192,Dihydroxymorphinone,10,17-dihydroxy-4-methyl-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7,9,11(18)-trien-14-one,3,14-Dihydroxy-4,5-alpha-epoxy-17-methylmorphinan-6-one,Oxymorphone cii,Morphinan-6-one,5.alpha.-epoxy-3,14-dihydroxy-17-methyl-,Numorphone,Oxymorphone (INN),Morphinone, dihydro-14-hydroxy-,CHEMBL963,D08323,14-Hydroxydihydromorphinone,OXYMORPHONE [WHO-DD],(4R,4aS,7aR,12bS)-4a,9-dihydroxy-3-methyl-2,4,5,6,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-one,DEA No. 9652,Oxymorphonum [INN-Latin],OXYMORPHONE [MI],4,5.alpha.-Epoxy-3,14-dihydroxy-17-methylmorphinan-6-one,SCHEMBL3571,DTXSID5023409,OXYMORPHONE [INN],opana,Oxymorphone,Oxymorphine,OXYCODONE HYDROCHLORIDE IMPURITY, OXYMORPHONE- [USP IMPURITY],NIH 10323,Oxymorphone solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material,Ossimorfone,OXYCODONE HYDROCHLORIDE IMPURITY A [EP IMPURITY],OXYMORPHONE CII [USP-RS],Oximorfona,MORPHINAN-6-ONE, 4,5-EPOXY-3,14-DIHYDROXY-17-METHYL-,OXYMORPHONE [VANDF],Oximorphonum,NSC19045,Oxymorphonum,HSDB 8060,Oxymorphone [INN:BAN],4,5-Epoxy-3,14-dihydroxy-N-methyl-6-oxomorphinan,Ossimorfone [DCIT],(5alpha)-4,5-Epoxy-3,14-dihydroxyl-17-methylmorphinan-6-one,GTPL7094,AKOS015962232,(-)-Oxymorphone,Morphinan-6-one, 4,5alpha-epoxy-3,14-dihydroxy-17-methyl- (8CI),(1S,5R,13R,17S)-10,17-dihydroxy-4-methyl-12-oxa-4-azapentacyclo[9.6.1.0^{1,13}.0^{5,17}.0^{7,18}]octadeca-7(18),8,10-trien-14-one,Morphinan-6-one, 4,5-epoxy-3,14-dihydroxy-17-methyl-, (5alpha)-,NSC 19045,Oxymorphone 0.1 mg/ml in Methanol,BRN 0041588,stopsigns,oxymorphone,Morphinan-6-one, 4,5alpha-epoxy-3,14-dihydroxy-17-methyl-,7,8-Dihydro-14-hydroxymorphinone,(14S)-14-Hydroxydihydromorphinone,(4R,4aS,7aR,12bS)-4a,9-dihydroxy-3-methyl-2,4,5,6,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinoline-7-one,Oxycodone hydrochloride impurity, oxymorphone-,Morphinone, 7,8-dihydro-14-hydroxy- (6CI,7CI),NSC-19045, Oxymorphone (abuse-resistant, pain), Pain Therapeutics/Pfizer,Morphinan-6-one, 4,5-epoxy-3,14-dihydroxy-17-methyl-, (5alpha)- (9CI),10,17-dihydroxy-4-methyl-(13R,17S)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10-trien-14-one(xymorphone),Opana,HY-B0618,Dihydrohydroxymorphinone,Oxymorphone (abuse-resistant, pain),ZINC3875483,9VXA968E0C,IDS-NO-003,Oximorfona [INN-Spanish]


Estimated data

Solubility: -2.462 (log(S) in mol/L prediction using SolTranNet)

Blood Brain Barrier Permeability: Yes (prediction using frontiersin.org)

Addictivity Prediction: 98.7% (prediction based on www.mdpi.com)

Similitudes

Voici une série de comparaisons visant à comprendre les propriétés de ce composé. Ce site est encore très expérimental et fait l'objet d'un développement actif. Veuillez vous référer à notre série d'articles d'articles pour bien comprendre notre approche et ses limites. Ces informations sont données à titre indicatif et ne doivent pas être interprétées comme des conseils médicaux.